The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma |
| |
| Authors: | Yasuhiro Oki Hubert Chuang Beth Chasen Aaron Jessop Tinsu Pan Michelle Fanale Bouthaina Dabaja Nathan Fowler Jorge Romaguera Luis Fayad Fredrick Hagemeister Maria Alma Rodriguez Sattva Neelapu Felipe Samaniego Larry Kwak Anas Younes |
| |
| Affiliation: | 1. Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, , Houston, TX, USA;2. Department of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, , Houston, TX, USA;3. Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, , Houston, TX, USA |
| |
| Abstract: | ![]()
The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non‐bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3‐year progression‐free survival rates in PET2‐negative vs. PET2‐positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non‐randomized studies of PET2‐guided therapy would be valuable with careful interpretation. |
| |
| Keywords: | Hodgkin lymphoma positron emission tomography prognostic |
|
|
